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Luteal phase deficiency (LPD) is described as a condition of insufficient progesterone exposure to maintain a
regular secretory endometrium and allow for normal embryo implantation and growth. Recently, scientific focus is
turning to understand the physiology of implantation, in particular the several molecular markers of endometrial
competence, through the recent transcriptomic approaches and microarray technology. In spite of the wide
availability of clinical and instrumental methods for assessing endometrial competence, reproducible and reliable
diagnostic tests for LPD are currently lacking, so no type-IA evidence has been proposed by the main scientific
societies for assessing endometrial competence in infertile couples. Nevertheless, LPD is a very common condition
that may occur during a series of clinical conditions, and during controlled ovarian stimulation (COS) and
hyperstimulation (COH) programs. In many cases, the correct approach to treat LPD is the identification and
correction of any underlying condition while, in case of no underlying dysfunction, the treatment becomes empiric.
To date, no direct data is available regarding the efficacy of luteal phase support for improving fertility in
spontaneous cycles or in non-gonadotropin induced ovulatory cycles. On the contrary, in gonadotropin in vitro
fertilization (IVF) and non-IVF cycles, LPD is always present and progesterone exerts a significant positive effect on
reproductive outcomes. The scientific debate still remains open regarding progesterone administration protocols,
specially on routes of administration, dose and timing and the potential association with other drugs, and further
research is still needed.
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Multiple uses of progesterone and progestogens for
women’s health in clinical practice are recognized. In
obstetric care they are used for treating abortion and
preterm labor prevention, and in gynecology to balance
estrogens in hormonal replacement therapies or in oral
contraception, and as palliative care for the treatment of
gynecological malignancies. On the other hand, the role
of progesterone for luteal phase support still represents
a controversial topic, due to its wide and empirically
transverse clinical use, from natural ovulatory cycles to
assisted reproductive technologies (ARTs). Most of these
controversies derive from too much confusion existing* Correspondence: stefanopalomba@tin.it
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LPD is described as a condition of insufficient proges-
terone exposure to maintain a normal secretory endo-
metrium and allow for normal embryo implantation and
growth [1]. This definition has been sustained during
years from its first description [2].
After several years where endometrium has received
much less attention in reproductive studies compared to
ovary and embryo development, the endometrium is
now receiving the research attention it deserves, due to
its physiological importance in reproduction [3]. In fact,
embryo implantation represents a critical step of the re-
productive process consisting of a unique biological
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blastocyst stage and a synchronized dialog between
maternal and embryonic tissues [5]. The human endo-
metrium undergoes a complex series of organized prolif-
erative and secretory changes in each menstrual cycle
and exhibits only a short period of receptivity, known as
the ‘implantation window’ [6]. Endometrial receptivity
during the implantation window requires a close cooper-
ation of an extremely large number of different factors;
unfortunately, the individual role of each factor in the
network of endometrial development is still not
completely understood [4].
The aim of this descriptive review will be to provide
clinicians with a brief document based on the best and
current scientific evidences, summarizing the actual
knowledge regarding the role of progesterone in im-
plantation physiology, and to show the potential and
correct use of progesterone and progestogens for treat-
ment of LPD in the different clinical settings. To obtain
evidence-based data, we performed a systematic search
for studies (articles and/or abstracts), without English
language limitation, collecting and analyzing the pub-
lished articles in literature until July 2015. We searched
on Medline (through PubMed), with the combination of
the following medical subject headings or keywords:
“luteal phase deficiency”, “window of implantation”,
“endometrial competence”, “progesterone AND luteal
phase support”, “assisted reproductive technologies
AND progesterone”, “controlled ovarian hyperstimula-
tion AND luteal phase support” and “frozen-thawed cy-
cles AND luteal phase support”. Additional literature
searches were performed on the references from the
identified studies. We gave priority to meta-analysis, sys-
tematic reviews and randomized clinical trials (RCTs),
based on the personal evaluation of each author. When
meta-analytic data or data from RCTs were lacking, pro-
spective non-randomized and then cohort studies were
included in the final analysis.
Implantation physiology
The uterus differentiates into an altered state when
implantation-competent blastocysts are ready to initiate
implantation. This state is called uterine receptivity for
implantation, i.e. the implantation window, and lasts for
a limited time. At this stage, the uterine environment is
conducive to blastocyst growth, attachment and the sub-
sequent events of implantation. The main hormones in-
volved in uterine receptivity are the ovarian steroids,
progesterone and estrogen. Uterine sensitivity to im-
plantation is classified into pre-receptive, receptive and
non-receptive (refractory) phases. In humans, the endo-
metrium is classified histologically and functionally into
proliferative and secretory phases during the average
28–30 day menstrual cycle. During the secretory phase,the uterus is considered pre-receptive for the first
~7 days following ovulation; it then becomes receptive
during the mid-secretory phase, which spans 7–10 days
after ovulation; the non-receptive (refractory) phase
comprises the rest of the secretory phase [7].
Molecular and genetic evidence indicates that locally
produced signaling molecules, including cytokines,
growth factors, homeobox transcription factors, lipid
mediators and morphogens, together with ovarian hor-
mones serve as autocrine, paracrine and juxtacrine fac-
tors to obtain uterine receptivity [8]. Therefore, the
implantation mechanism includes the cooperation of
several factors, such as the integrins on both blastocyst
and receptive endometrium surfaces, progesterone
which stimulates the endometrium receptivity and the
decidulization of stroma and a series of cytokines, such
as IL-1 and EGF, which participate in the regulation of
endometrial immune tolerance, expression of integrin
nd prostaglandins production [7, 8].
The corpus luteum is derived from the transformation
of granulosa and theca cells into luteal cells in response
to the mid-cycle surge of gonadotropins or to an ex-
ogenous human chorionic gonadotropin (hCG) bolus ad-
ministration. The most important function of the corpus
luteum is progesterone secretion which is necessary to
obtain a secretory transformation of the endometrium
and to sustain the early pregnancy. Progesterone pre-
pares the endometrium for pregnancy by stimulating
proliferation in response to hCG. This occurs in the
luteal phase of the menstrual cycle.
During the midluteal phase of a natural cycle, proges-
terone is involved in the modulation process of the
expression of ultrastructural hallmarks of secretory
transformation, such as giant mitochondria, subnuclear
glycogen deposits, pinopodes and nucleolar channel sys-
tem (NCS) [9]. With the aim of inducing endometrial
competence/receptivity, progesterone can also act by
stimulating the immune system to produce non-
inflammatory T-helper 2 cytokines and C3-C4, as shown
in patients with autoimmune diseases [10, 11], increas-
ing nitric oxide production, with improvement of the
blood flow and oxygen to the endometrium [12]. Proges-
terone is also able to reduce the contractility of the
myometrium at the time of the implantation [13].
The crucial role of the corpus luteum in human
reproduction in the maintenance of early pregnancy is
demonstrated by the harmful effects of a lutectomy during
the first weeks of a pregnancy. Initial studies on corpus
luteum function demonstrated that, in patients at 7 weeks
of pregnancy, after a tubal ligation, the plasma progester-
one levels were normal and pregnancy continued but,
after a tubal ligation plus lutectomy, the plasma progester-
one levels dropped to near zero within 5 days and the
pregnancy was aborted [14]. In this week of gestation,
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ment was effective in maintaining the pregnancy. At and
after 8 weeks of amenorrhea, tubal ligation plus lutectomy
decreased plasma progesterone levels until day 4 but these
then increased to pre-treatment concentrations with suc-
cessful continuation of pregnancy [14].
This “genuine” endometrial competence, however, can
be negatively affected in clinical practice by several func-
tional diseases, such as polycystic ovarian syndrome
(PCOS) and obesity [15] and anatomic abnormalities,
such as congenital uterine anomalies [16], endometrial
polyps [17], myomas (submucosal) [18], hydrosalpinx
[19] and endometriosis [20]. In fact, the treatments of
these diseases have been discussed as potential therapies
to improve fertility and clinical pregnancy rate in spon-
taneous and/or in in-vitro fertilization (IVF) cycles. The
pregnancy rate was found to be two-fold higher [relative
risk (RR) 2.0, 95 % confidence interval (CI) 1.1 to 3.9]
after myomectomy of submucosal myomas [18] or after
polipectomy of 3–24 mm endometrial polyps (RR 2.1,
95 % CI 1.5 to 2.9) [21]. Laparoscopic salpingectomy for
hydrosalpinges versus no-surgical treatments improved
the clinical pregnancy rate by more than two-fold [odds
ratio (OR) 2.49, 95 % CI 1.60 to 3.86) [19]. Finally, com-
pared with diagnostic laparoscopy, laparoscopic surgery
for endometriosis was associated with a significant im-
provement of the clinical pregnancy rates (OR 1.89,
95 % CI 1.25 to 2.86) [20].
Endometrial competence evaluation
Endometrial competence can be assessed using different
methods, such as histology, timing, ultrasound and
biomarkers.
In consideration of the LPD definition, histological
evaluation of the endometrium has been considered the
gold standard procedure to study endometrial compe-
tence. The histological method is based on a careful exam-
ination of an endometrial biopsy, and on the definition of
the histologic characteristics of a secretory endometrium
and describing the temporal responses to progesterone,
i.e. endometrial dating. An endometrium is considered
out of phase when there is a lag of more than 2 days [22].
Over the years, the histological method has developed
more specific instruments, such as scanning electron mi-
croscopy [23, 24] and the immunohistochemical analysis
of estrogen and progesterone receptors [25]. However,
randomized clinical trials (RCTs) suggest that endometrial
biopsy is an inaccurate tool for differentiating fertile
women from women with LPD and infertility [1].
The timing as criteria of endometrial competence is
based on LH peak, ultrasound demonstration of ovula-
tion, basal body temperature shift and menstrual flow
after the biopsy but it also presents a wide inter- and
intra-subject variability [1, 26].Ultrasound assessment is still used to evaluate endo-
metrial competence though no significant correlation
has been seen between endometrial measurement
(>7 mm) and the pregnancy rate; moreover, the triple-
layered pattern is visible in the same rate in infertile
and fertile women (91 % vs. 90 %, respectively) [27].
In order to increase accuracy of the ultrasound
method and to find a predictor sign of pregnancy
during IVF-treatment, the power-Doppler was pro-
posed as the instrument for evaluating endometrial
competence, but no statistically significant differences
in the vascularization indexes of endometrial and sub-
endometrial blood flows were found between pregnant
and non-pregnant groups [28].
Several molecular markers of endometrial competence
have been discovered in blood and uterine fluid analysis
and endometrial biopsy, such as estradiol, progesterone,
pinopodes, glycodelin, IL-1 system, cytokines, integrins
and HOXA genes [29]. Serum progesterone assay has
been proposed as surrogate of endometrial competence
but it has been observed that no minimum progesterone
levels can define a “fertile” luteal phase [30] because pro-
gesterone concentrations may fluctuate up to eightfold
within 90 min [31] and its levels peak 6 to 8 days after
the ovulation [32].
Among the over one hundred different genes identi-
fied, all potential biomarkers of the implantation win-
dow, few studies exist with adequate power and validity
based on study design to help determine which bio-
markers have the greatest value and consistency; there-
fore, no reliable methods to assess “receptivity” have
been established or adequately validated [33]. Neverthe-
less, the transcriptomic approaches and microarray tech-
nology make it possible to identify biomarkers of
endometrial receptivity and to report modifications re-
lated to the gene expression profile associated with the
transition of the human endometrium from a pre-
receptive to a receptive state during a natural cycle and,
most of all, to reveal either moderate or strong alter-
ations of endometrial receptivity under controlled ovar-
ian stimulation (COS) protocols [34]. In fact, a study
analyzed the endometrial gene expression profiles by
paired samples from the same patients during the pre-
receptive to the receptive transition both in a natural
and a subsequent stimulated cycle [34]. This study has
shown that COS regimens affect the transcriptomic pat-
tern of endometrial cells in comparison with natural cy-
cles; in particular, there were numerous differences in
the main systems involved in the implantation process,
such as the TGFb signaling pathway, the complement
and coagulation cascades and leukocyte transendothelial
migration [34]. This information could open new per-
spectives, particularly in patients with multiple im-
plantation failures [34]. A recent study revealed that
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associated with an aberrant gene expression profile,
particularly of transcripts related to the immune
function and complement activation, and altered
progesterone signaling might be an underlying mech-
anism for such endometrial gene expression deregu-
lation in women with repeated implantation failure
[35]. Other research has been focused on the family
of fibroblast growth factors (FGFs), which affects
embryo implantation and supports improved endo-
metrial trophoblastic interaction [36]. Compared with
the fertile group, FGF-1 is not expressed strongly
enough in the failed IVF patients, which may have
caused a lack of endothelial cell migration, important
for implantation, stopped the process of blood vessel for-
mation or induced early vascularization of implantation
problems [37].
However, in the current state, no type-IA evidence
has been proposed by the main scientific societies for
assessing endometrial competence in infertile couples.
In fact, the Royal College of Obstetricians & Gynecol-
ogists (RCOG) guidelines for infertility do not recom-
mend the use of basal body temperature charts nor
an endometrial biopsy to evaluate the luteal phase in
routine infertility investigation [38]. The blood test
measurement of serum progesterone in the mid-luteal
phase of the cycle is recommended but with type-B
evidence [38]. At the same time, according to the
recommendation of the American Society for Repro-
ductive Medicine (ASRM), no diagnostic test for lu-
teal phase insufficiency has been proven to be reliable
in a clinical setting [1].Luteal phase support in clinical practice
The discussion regarding the clinical role of LPD is
mainly due to the lack of reproducible and reliable
diagnostic tests. Nevertheless, LPD is a common
condition, that occurs during a series of clinical pat-
terns characterized by low follicular-stimulating hor-
mone (FSH) levels, altered follicular FSH/luteinizing
hormone (LH) ratio and/or abnormal FSH and LH
pulsatility, such as functional hypothalamic amenor-
rhea, thyroid and prolactin disorders [39], obesity
and PCOS [15] and during COS for IVF cycles [40].
Therefore, the correct approach to the treatment
of LPD is the identification and correction of any
underlying condition. On the other hand, in case of
no underlying dysfunction, the treatment becomes
empiric [1].
Notwithstanding the empiricism of the LPD treatment,
there are different clinical conditions where luteal phase
support may be more or less useful, and can drive the
choice for a specific luteal phase support.Spontaneous ovulatory cycles
In spontaneous cycles there are no direct data on the ef-
ficacy of luteal phase support for improving fertility. A
recent Cochrane meta-analysis on miscarriage preven-
tion showed no statistically significant difference be-
tween women receiving progestogens (either natural and
synthetic) and those receiving only placebo or no treat-
ment (OR 0.99, 95 % CI 0.78 to 1.24) [41]. The same
meta-analysis found a statistically significant reduction
(OR 0.39, 95 % CI 0.21 to 0.72) in miscarriage rate after
progestogen administration only in women with recur-
rent miscarriage, i.e. three or more consecutive miscar-
riages. Moreover, these findings deserve further studies
because the trials included were of poorer methodo-
logical quality [41]. Also for the treatment of threatened
miscarriage, there is insufficient evidence to support the
routine use of progestogens (whether natural or syn-
thetic) [42]. In conclusion, in natural and unstimulated
cycles, no treatment for LPD has been shown to improve
pregnancy outcomes [1].
Non-gonadotropin induced ovulatory cycles
The non-gonadotropin induced ovulatory cycles
mainly use clomiphene citrate (CC), while aromatase
inhibitors (AIs) and metformin are still considered ex-
perimental treatments and to be employed in selected
cases, respectively.
CC is a nonsteroidal selective estrogen modulator with
both estrogenic and anti-estrogenic properties that inter-
feres with the normal feedback mechanisms and leads to
increased and prolonged FSH and LH secretion, which
in turn stimulates follicular development. Cumulative
CC administrations induce weak and prevalent anti-
estrogenic effects on sensitive tissues, such as endomet-
rium and/or ovary-related luteal phase defect and/or fol-
liculogenesis alterations [43]. The competitive binding of
the CC with estrogen receptors makes the estrogenic sen-
sitive organs less-sensitive to endogenous and exogenous
steroid [43]. Moreover, CC administration appears to be
related to a reduced perifollicular vascularization and to a
rate of high grade follicles significantly lower than in
healthy controls [44]. Also the vascularization of corpus
luteum is significantly lower and with higher resistance in
CC cycles, considering this hypo-vascularization of corpus
luteum as a possible LPD cause [44].
To this regard, several data are available in literature
about luteal phase progesterone support after ovulation
induction in intrauterine insemination (IUI) cycles. A re-
cent meta-analysis concluded that progesterone support
did not benefit the clinical pregnancy rate in patients
undergoing ovulation induction with CC (RR 0.89, 95 %
CI 0.47 to 1.67) nor a significant difference in miscar-
riage per cycle between the two groups (OR 1.03, 95 %
CI 0.52 to 2.04) [13]. Of note, no heterogeneity in the
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on live birth to perform data synthesis. The same results
were obtained in another recent meta-analysis [45]. In
CC-stimulated cycles, progesterone administration did
not improve the reproductive outcomes, such as the live
birth rate (RR 1.30, 95 % CI 0.68 to 2.50) and the clinical
pregnancy rate (RR 1.17, 95 % CI 0.82 to 1.65) and no dif-
ferences were observed regarding miscarriage rate between
the progesterone-treated and not-treated groups in the CC
stimulation protocol (RR 1.14, 95% CI 0.63 to 2.06) [45].
In CC-stimulated cycles, the combined administration
of estrogens and progesterone was tested in clinical
studies showing not univocal results. In fact, endometrial
estrogen receptors are blocked by competitive binding of
the CC. Thus, they could be not stimulating by estro-
gens. Moreover, a RCT demonstrated that ethinylestra-
diol administration from day 8 for 5 days (0.05 mg daily)
significantly improves the efficacy of progesterone sup-
port administered intramuscularly [46]. Similarly, an-
other RCT showed a significant reproductive benefit of
oral estradiol administration (3 mg daily in two adminis-
trations from cycle day 8 until ovulation) followed by va-
ginal progesterone in CC cycles [47]. Finally, a very
recent randomized, double-blind, placebo-controlled
trial compared in PCOS women the clinical pregnancy
rate between two groups treated with CC plus ethinyl
estradiol and CC plus placebo, respectively. The study
resulted in an increase of clinical pregnancy rate in the
CC + EE group (29 % vs 10 %, p = 0.02) even if there
was no statistically significant difference in the ongoing
pregnancy rate between the two groups [48]. However,
an interesting recent retrospective cohort analysis re-
vealed that luteal phase progesterone supplementation
in CC-IUI cycles can improve endometrial receptivity
with an effect closely related to the endometrial thick-
ness [49]. Patients who appeared to receive the greatest
benefit of progesterone supplementation had an endo-
metrial thickness of 6–8 mm; their clinical pregnancy
rate was found to be improved two-fold (OR 2.04; 95 %
CI 1.01 to 4.14) [49]. These patients seem to have an
endometrium still receptive to progesterone administra-
tion, whereas patients with an endometrial thickness less
than 6 mm are not responsive to progesterone supple-
mentation for CC-related receptors depletion/inhibition
and patients with an endometrial thickness greater than
8 mm represent a group with good reproductive progno-
sis in which progesterone supplementation is unable to
provide further reproductive improvement.
Metformin improves the regular menstrual cycles and
increases ovulation rate in patients with PCOS, although
the efficacy of the drug is extremely variable both between
different PCOS populations and within the same popula-
tion [50]. The efficacy of metformin in inducing ovulation
in patients with PCOS is probably due to a direct actionof the drug on the ovary; in fact, the ovulatory response to
the drug seems to be related more to local drug sensitivity
or resistance than to improvements in the systemic hor-
monal and/or metabolic environments [51], as shown by
the analysis of follicular fluid that seemed to confirm that
metformin acts directly on the ovary, improving local
levels of androgens, ovarian insulin resistance and the
levels of several growth factors [50]. As regards the use of
metformin as ovulation inductor, unfortunately few and
no direct data exist concerning the need of a luteal phase
support. Under metformin treatment, the hormonal pat-
tern and the ovarian dynamics of the ovulatory cycles
were found to be similar to spontaneous cycles as ob-
served in normo-ovulating controls [52]. In addition, the
preovulatory follicles obtained under metformin treatment
had a vascularization similar to that observed during nat-
ural cycles of healthy women, and the rate of high grade
preovulatory follicles observed in women with PCOS who
ovulated with metformin was not significantly different
from controls [44]. Finally the vascularization around the
corpus luteum was found to be similar between metfor-
min and spontaneous cycles, confirming the beneficial ef-
fects of metformin on the corpus luteum function [44].
Letrozole is an aromatase inhibitor recently employed
as ovulation inducer. A recent large multicenter ran-
domized double-blind parallel controlled trial, published
in 2014, demonstrated the superiority of letrozole as
first-line therapy for anovulatory infertility in women
with PCOS when compared with CC [53]. A systematic
review of RCTs with meta-analysis concluded that letro-
zole is associated with significantly higher live birth rates
than with CC (OR 1.64, 95 % CI 1.32 to 2.04) and with
significantly higher clinical pregnancy rate compared to
CC (OR 1.40, 95 % CI 1.18 to 1.65) even if the quality
of the evidence was rated as low [54]. Letrozole acts by
inhibiting the aromatase, a cytochrome P450 enzyme
complex which is responsible for androgen to estrogen
conversion, so it induces a hypoestrogenic state that
stimulates, through activation of hypothalamic-pituitary
axis, increased FSH secretion and ovarian follicle devel-
opment [43]. It does not exert an antagonist effect on
endometrial estrogen receptors; on the other hand sup-
pression of the systemic estrogen levels and in peripheral
tissues can result in up-regulation of the estrogen recep-
tors in the endometrium, leading to rapid endometrial
growth once follicle development starts and estrogen
secretion is restored [43].
Controlled ovarian stimulation (COS) with
gonadotropins for non-IVF cycles
In non-IVF cycles with gonadotropins COS, two recent
meta-analyses [45, 46] have demonstrated the benefit in
improving reproductive outcomes with vaginal proges-
terone use as luteal phase support. Specifically, in the
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to 70 % (OR 1.77, 95 % CI 1.20 to 2.60), as well as the likeli-
hood of live birth per cycle (OR 2.63, 95 % CI 1.42 to 4.80),
in patients receiving progesterone support [45]. In the sec-
ond meta-analysis, patients treated with FSH showed
higher biochemical pregnancy (RR 1.81, 95 % CI 1.36 to
2.43), clinical pregnancy (RR 1.57, 95 % CI 1.15 to 2.15)
and live birth (RR 2.28, 95 % CI 1.49 to 3.51) rates on re-
ceiving progesterone supplementation [46]. No differences
were observed regarding miscarriage rate between the
two study groups (progesterone treated and not-
treated groups) [46]. In both meta-analyses [45, 46],
data heterogeneity was low and not significant.
To the regard of the optimal progesterone dosage to
use in non-IVF COS cycles with gonadotropins, very few
clinical evidences are available in literature. A very re-
cent RCT, evaluating two doses of vaginal progesterone
for IUI cycles in terms of pregnancy rates, demonstrated
that 300 mg of intravaginal micronized progesterone
should be the maximum dosage for luteal phase when
compared with 600 mg [55].
Controlled ovarian hyperstimulation (COH) with
gonadotropins for IVF cycles
To explain in detail the role of progesterone and/or pro-
gestogens for the luteal phase support in gonadotropins
COH for IVF cycles, the issue should be approached
considering conventional and new protocols of gonado-
tropins COH separately.
Conventional COH protocols
Conventional COH protocols with gonadotropins have
seen the transition over time from use of depot GnRH-
agonist plus high-dose gonadotropins (225 IU/daily) in
step-down or chronic regimen to daily GnRH-agonist plus
low-doses gonadotropin (150 IU/day) in the patients’ re-
sponse adjusted regimen, i.e. a “mild stimulation”. Ovarian
hyper-stimulation was seen to affect embryo quality as
assessed by morphology as well as the chromosomal con-
stitution of the embryos [56–58], as result of interference
with the natural selection of good-quality oocytes or the
exposure of growing follicles to the potentially negative ef-
fects of ovarian stimulation [59]. Mild stimulation ap-
proaches, aiming at a more physiological response, seem
to improve embryo quality [59]. In fact, a meta-analysis
combining the results of three separate RCTs suggests that
the retrieval of a reduced number of oocytes following
mild stimulation is associated with a higher implantation
rate compared with patients where the same number of
oocytes is retrieved following conventional stimulation
[60]. Mild stimulation approaches might improve also em-
bryo implantation rates [61].
In both these conventional COH for IVF cycles, an LFD
is always present and it is due to supra-physiologicalestradiol levels which inhibit LH release, as negative
feed-back mechanism, and alter endometrial respon-
siveness to progesterone [62]. Moreover, the use of
GnRH agonist [63] and antagonist [64] implies luteoly-
sis and decreased LH pulsatility because of a competi-
tive receptor’s blockage.
As result, in conventional IVF cycles, after hCG trig-
ger, hCG levels rapidly increase until maximum levels at
the time of oocyte retrieval, before falling to the lowest
levels approximately 5 days after the retrieval [65]. The
trend of progesterone follows that of hCG more slowly,
with a peak near to 5 days after oocyte retrieval, then de-
creases rapidly [66]. Therefore, it creates a window dur-
ing which progesterone lacks hCG stimulation to reach
the threshold of 80–100 nmol/L, necessary to maintain
the pregnancy [67]. The luteal support is required in this
time interval.
The main guidelines of the scientific society agree to
recommend exogenous progesterone supplementation in
assisted reproductive technologies (ARTs) cycles [68, 69].
A recent Cochrane meta-analysis regarding luteal phase
support for ARTs cycles confirmed that progesterone ex-
erts a significant positive effect on clinical pregnancy (OR
1.89, 95 % CI 1.30 to 2.75) and on pooled live birth or on-
going pregnancy (OR 1.77, 95 % CI 1.09 to 2.86) rate [70].
However, when the analysis was restricted to live birth
rate alone, evidence suggested no significant effect of the
progesterone administration (OR 4.21, 95 % CI 0.93 to
19.18) [70]. Surprisingly, in a previous Cochrane review
[71] the same authors concluded that progesterone had a
significant positive effect on live birth rate compared to
placebo, although in both reviews the effect of progester-
one on the live birth derived from the results of a single
study. In the most recent Cochrane [70], no significant
data heterogeneity was detected, although the quality of
the evidence was considered as very low to low. On the
other hand, even if the hCG administration for luteal
phase support is also effective, i.e. no differences between
progesterone and hCG in rates of live birth or ongoing
pregnancy (OR 0.95, 95 % CI 0.65 to 1.38), its use in-
creases the ovarian hyperstimulation syndrome (OHSS)
risk by more than four-fold compared to placebo (OR
4.28, 95 % CI 1.91 to 9.60) and compared to the progester-
one group (OR for OHSS of progesterone group vs. hCG
group: 0.50, 95 % CI 0.34 to 0.76) [70].
Progesterone has different pharmacokinetic and
pharmacodynamics properties when used in different
routes of administration. In fact, intramuscular proges-
terone in oil formulation is related to higher serum pro-
gesterone concentrations and lower endometrial
concentrations (unlike vaginal route) [72]. In addition, in
consideration of a half-life longer than one day, a depot
effect with a continuous release over time without inter-
mittent peaks (as in the case of vaginal route) has been
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pharmacokinetic properties of intramuscular route allow
a wider implantation window and less endometrial con-
tractions per minutes on the day of the embryo transfer
(1 vs. more than 4 endometrial waves) [73]. Unfortu-
nately, intramuscular progesterone in oil formulation is
available only in a few countries and represents a very
painful route of administration. Similarly, the other
available options for delivering exogenous progesterone
have other restrictions, such as a low absorption rate for
oral administration, due to the first liver-pass effect and
potential side effects due to its metabolites, or the need
for daily repeated administrations of vaginal progester-
one, which can result in an uncomfortable route and
with absorption variability due to leakage [74]. Different
routes of progesterone administration have been compared
in clinical studies. An initial meta-analysis [75] found no
significant differences in treatment outcomes between va-
ginal and intramuscular progesterone administration. More
recently, also a new systematic review and meta-analysis
[70] showed that there were no statistically significant dif-
ferences in live birth rate between intramuscular vs. oral
(OR 0.71, 95 % CI 0.14 to 3.66) and vs. vaginal or rectal
(OR 1.31, 95 % CI 0.84 to 2.05) route. The same statistical
inconsistence remained between the different routes of ad-
ministration also when other intermediate endpoints, such
as the clinical pregnancy rate, were evaluated [70]. More-
over, results were obtained after data extrapolation from
few studies on little study’ populations [70].
Regarding to the dose of progesterone, the most recent
Cochrane review demonstrated no differences in live
birth or ongoing pregnancy rate (OR 0.97, 95 % CI 0.84
to 1.11) between standard (90 mg/day) or high (equal or
more than 100 mg/day) doses of vaginal progesterone
without heterogeneity among studies [70]. Moreover, the
RCTs synthesized included different formulations and
were of suboptimal quality. Both histopathological [76]
and clinical studies [77] suggested that vaginal proges-
terone in doses lower than 300 mg/day are less efficacy
to intramuscular progesterone (100 mg daily) whereas
no difference in efficacy was demonstrated when doses
of 600 mg/day of vaginal progesterone were used [78].
In addition, another recent RCT comparing low-dose of
micronized vaginal progesterone (200 mg twice daily)
versus high-dose (200 mg three times daily) confirmed
that the first regimen is less effective in term of clinical
and ongoing pregnancy [79]. Moreover, a noninferiority
RCT found no statistical differences in clinical pregnancy
rate, implantation rate and miscarriage rate between intra-
muscular (50 mg/day) and vaginal progesterone, when ad-
ministrated as micronized progesterone bioadhesive gel
both at standard (90 mg/day) and high-dosage (90 mg
twice a day) [80]. The efficacy of micronized progesterone
in bioadhesive gel formulation (90 mg/day) was alsoconfirmed in a multicentre RCTs demonstrating no statis-
tical differences in live-birth rate and pregnancy rates
when compared with other vaginal formulations (100 mg),
although used at higher dosages [81, 82].
The goals for new progesterone treatment seem to be
represented by aqueous subcutaneous progesterone.
Two large multicentre RCTs demonstrated that the
25 mg subcutaneous progesterone administered once
daily is effective and well tolerated [83, 84]. Both 25 and
50 mg daily doses of aqueous subcutaneous progester-
one led to similar secretory transformation of endo-
metrium in reproductive-aged women who were
down-regulated with GnRH agonist and treated with
estradiol [85] suggesting that 25 mg should be con-
sidered the lowest effective dose. The subcutaneous
administration maximizes the kinetic profile and the
physiological response, i.e. lower dose needed, minim-
izing side effects [85, 86]. In fact, it reduces patient
discomfort (fewer skin reactions) and it may be ap-
pealing to women who prefer to avoid the intramus-
cular and vaginal routes of administration [84]. This
dose also relates to the daily production of progester-
one, which has been estimated to be 25 mg.
Other compounds were assessed alone or in combin-
ation with progesterone for luteal phase support in con-
ventional IVF cycles. As explained earlier, hCG should
be avoided as it leads to a higher risk of OHSS (see
above) and the addition of estrogens to progesterone did
not show a better effect than progesterone alone in the
rates of ongoing pregnancies (OR 1.12, 95 % CI 0.91 to
1.38) and live births (OR 1.32, 95 % CI 0.93 to 1.86)
[70]. The only significant result was found in the com-
parison of progesterone versus progesterone plus GnRH
agonists [70]. Specifically, the addition of GnRH agonist
to progesterone had a significant greater effect than pro-
gesterone alone in live birth rate (OR 0.40, 95 % CI 0.26
to 0.61), clinical pregnancy rate (OR 0.71, 95 % CI 0.59
to 0.87) and pooled live birth/ongoing pregnancy rate
(OR 0.67, 95 % CI 0.56 to 0.81) [70]. Although a high
statistical heterogeneity was detected in this analysis, the
direction of the effect was considered consistent. The ef-
fectiveness of the GnRH agonist administration in luteal
phase support has been confirmed both in GnRH agon-
ist and GnRH antagonist COHs [87]. Moreover, the lu-
teal support with GnRH agonist requires repeated daily
administrations. In fact, due to the pharmacokinetics of
the GnRH agonist-induced LH releases (see below), a
clear-cut positive correlation between the frequency of
GnRH agonist administration (i.e., buserelin) and serum
progesterone levels was observed [88, 89].
In literature, there is a debate regarding also the timing
of progesterone administration, once a decreased likeli-
hood of pregnancy has been observed if progesterone is
initiated both before oocyte retrieval or 6 days after oocyte
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of 872 patients and 1010 cycles shows the presence of a
window for progesterone start, occurring between the
evening of oocyte retrieval and day 3 after oocyte retrieval,
when the embryo-to-endometrial synchrony and exogen-
ous luteal phase support seem to be optimized [90]. Of
these RCTs, only one reported live birth rates, finding no
differences in live birth between patients randomized to
receive progesterone 36 h before oocyte retrieval, the
evening of the oocyte aspiration or day 3 after oocyte re-
trieval [91] even if this study was not powered to detect a
difference in live birth rate. In fact, all studies reported the
clinical pregnancy rate as a primary outcome. A lower
clinical pregnancy rate was detected in patients starting
progesterone 12 h before oocyte retrieval compared with
those patients starting progesterone the evening of oocyte
retrieval (12.9 % vs. 24.6 %, respectively; P = 0.01) [92].
Similarly, a lower clinical pregnancy rate was observed in
patients undergoing fresh autologous IVF and starting
progesterone 6 days after oocyte retrieval when compared
with starting progesterone 3 days after oocyte retrieval
(44.8 % vs. 61.0 %, respectively; P = 0.05) [93]. Finally, the
last three studies that compared the clinical pregnancy
rate in patients starting progesterone the evening of oo-
cyte retrieval versus 2 days after and 3 days after oocyte
retrieval did not detect significant differences between the
groups [91, 94, 95].
The optimal duration of progesterone supplementation
after IVF cycles has also been the object of debate. A
meta-analysis assessed the effects of different lengths of
progesterone treatment [96]. No statistical difference in
live birth (RR 0.95, 95 % CI 0.86 to 1.05), miscarriage
(RR 1.01, 95 % CI 0.74 to 1.38) and ongoing pregnancy
(RR 0.97, 95 % CI 0.90 to 1.05) rate between an early
progesterone cessation at the first positive pregnancy
test and a progesterone continuation until 6th-7th
weeks of pregnancy was observed [96]. No or low
heterogeneity was observed among studies in the
main outcome measures [96].
Non-conventional COH protocols
In order to optimize the safety of the COH in selected
populations, such as cancers patients and donors, new
COH protocols have been initially proposed, and further
extended to hyper- and normo-responders to achieve the
“OHSS-free clinic” dream [97]. The “non-conventional”
COH protocols consist of using GnRH antagonist for
avoiding LH surge and standard/high gonadotropin dos-
age [98, 99]. In case of no or low OHSS risk, multiple ovu-
lation triggering can be induced by conventional hCG
administration [98–103]. On the other hand, in case of
moderate and/or high OHSS risk, GnRH agonist super-
ovulation triggering followed by elective [100–103] or
non-elective cryopreservation programs (segmentation ofIVF cycles) [98, 99] can be an option. The “IVF cycle seg-
mentation” consists in the cryopreservation of all embryos
produced and their replacement in a receptive non-
stimulated endometrium, such as in a natural cycle, or
after artificial endometrial preparation [104]. This concept
is also supported by positive reproductive outcomes of
existing RCTs in favor of a strategy of frozen embryo
transfer, although same aspects remain unclear as well as
the higher incidence of “large baby syndrome” [105].
Thus, larger trials are needed before a critical change in
clinical practice can be widely accepted [106].
From the first study analyzing the potential role of
GnRH agonist to induce final follicular maturation, the
concern of a deep LPD in these IVF cycles and the need of
an intensive luteal phase support emerged [107]. The use
of standard treatment to support the luteal phase after
GnRH agonist triggering is considered inadequate in con-
sideration of the lower conception rates observed [108]. In
fact, GnRH agonist triggering shows a combined negative
effect on the function of the corpus luteum and on the
function of the endometrium [109, 110].
Relevant differences exist regarding the duration and pro-
file of the GnRH agonist-induced surge of gonadotropins
when compared with that of the natural cycle [111, 112].
The GnRH agonist-induced LH surge consists of two
phases: a short ascending limb of about 4 h and long de-
scending limb of about 20 h for a total length of 24–36 h.
On the other hand, the mid-cycle LH-surge of a natural
cycle is characterized by three phases: a rapidly ascending
phase lasting 14 h, a plateau of 14 h and a descending phase
of 20 h, for a total length of 48 h [113]. Therefore, the
total amount of LH released during the surge is sig-
nificantly reduced when GnRH agonist is used to trig-
ger ovulation compared with that in natural cycle or
with hCG triggering [113]. Moreover, the LPD after
GnRH agonist triggering is not due to low serum LH
levels but to the rapid half-life of LH. In fact, LH
levels of 4–10 IU/L are sufficient to induce a physio-
logic peak of progesterone (25 nmol/L) [67], and even
if the triggering with hCG induces a release in progester-
one higher than 100–250 nmol/L, the serum progesterone
levels of 80–100 nmol/L, as obtained after GnRH agonist
triggering, should be sufficient to support the luteal phase
[67, 114]. On the other hand, the half-life of LH is ap-
proximately 21 min vs. the half-life of hCG that is 12 h
[115]. Thus, the mean duration of a non-supplemented lu-
teal phase after GnRH trigger may be as short as 4 days,
compared with 13 days after hCG trigger [116].
Finally, biological changes in endometrium related to
GnRH agonist use were also observed. In particular, dif-
ferences were seen in endometrial gene expression, re-
lated to the type of ovulation trigger and luteal support.
The mode of triggering is reflected in the transcriptome
of the somatic cells of the follicle since they differentially
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granulosa cells. This suggests an impaired induction of
angiogenesis in the GnRHa-triggered as compared with
the hCG-triggered, which in association with the lower
postovulatory LH activity, and may explain the insuffi-
cient luteal phase observed after COH and GnRHa trig-
ger [117]. A RCT showed that the gene expression after
GnRH-a trigger and the modified luteal support adding
LH/hCG activity more closely resembles the pattern
seen with the use of hCG for trigger and of a standard
luteal support with vaginal progesterone [118].
The final result is a deeper LPD in GnRH agonist trig-
gering cycles compared with hCG triggering cycles. Ac-
tually, the scientific debate still remains open regarding
the role of GnRH agonist in trigger ovulation because
the most recent and updated Cochrane review [119]
about GnRH agonist vs. hCG for oocyte triggering in an-
tagonist ARTs largely confirmed the same conclusions as
the previous one [120]. In particular, the Authors con-
cluded that GnRH agonist, as a final oocyte maturation
trigger in fresh autologous cycles, is associated with a
lower live birth rate, a lower ongoing pregnancy rate
(beyond 12 weeks of amenorrhea) and a higher rate of
early miscarriage (less than 12 weeks) [119]. Thus,
GnRH agonist triggering could be useful and employed
only for women who choose to avoid fresh transfers,
women who donate oocytes to recipients or women who
wish to freeze their eggs for later use [119]. In reality, a
data synthesis of reproductive results may be not feasible
since the studies included were not comparable due to
difference in luteal phase support protocols [121].
New and different regimens have been proposed for a
greater luteal phase support in GnRH-a triggering: the
intensive or “American” approach which consists of an
aggressive steroidal support (intramuscular or vaginal
progesterone plus transdermal estradiol) with adjuvant
low-dose hCG trigger only in selected cases, such as
women with peak serum E2 less than 4000 pg/ml on the
day of trigger, and the moderate or the “European” ap-
proach which promotes the production of endogenous
steroids by the corpus luteum via exogenous hCG sup-
plementation, immediately after the oocyte retrieval, at
dose low enough to avoid the development of OHSS
[108]. Youssef et al. [119] highlighted that the modified
luteal phase support with LH/hCG (the European con-
cept) is associated with pregnancy rates almost compar-
able with those of hCG triggering cycles, albeit still
significantly lower. Another regimen suggested for a
more sustained luteal support is the use of one bolus of
1500 IU hCG concomitant with GnRH-a (dual trigger)
34–36 h before oocyte retrieval [122, 123]. With the dual
trigger, acceptable rates of implantation, clinical preg-
nancy, ongoing pregnancy rates, and early pregnancy
loss has been achieved in high responders [122, 123],even if the incidence of clinically significant OHSS was
not eliminated, but rather reduced to 0.5 % [123]. In
fact, the minimal hCG activity needed for luteal phase
support without inducing late-onset OHSS is not known.
In a RCT, two cases of moderate OHSS out of 125 pa-
tients (considered normal responders) treated with
GnRH agonist triggering plus 1500 IU hCG on the day
of oocyte retrieval and an additional bolus of 1500 IU of
hCG 5 days after the oocyte retrieval were reported
[124]. Thus, that protocol for luteal phase should be
avoided because of a persistent OHSS risk [124]. Finally,
a case of recurrent empty follicle syndrome has recently
been described, successfully treated by ovulation trigger
with GnRH-a 40 h and hCG added 34 h prior to oocyte
retrieval (double triggering) [125]. This new regimen is
based on the concept of prolonging the time interval be-
tween ovulation triggering with GnRH-a and oocyte re-
trieval [126] with the consequent simultaneous induction
of an FSH surge; thus the "double trigger" could overcome
any existing impairments in granulosa cell function, oo-
cyte meiotic maturation or cumulus expansion, resulting
in successful aspiration of mature oocytes, pregnancy and
delivery [127]. In line with these results, the double trig-
gering was later offered also to two groups of patients
demonstrating abnormal final follicular maturation des-
pite normal response to COH, those with low (<50 %)
number of oocytes retrieved per number of dominant fol-
licles (i.e. > 14 mm in diameter) on the day of hCG ad-
ministration [128] and those with low proportion of
mature/metaphase-II (MII) oocytes (<66 %) per number
of oocytes retrieved [129]. In both groups, with double
triggering, patients showed significantly higher number of
oocytes retrieved, higher number of mature oocytes per
number of oocytes retrieved, with a tendency toward a
higher number of top-quality embryos, as compared to
the hCG-only trigger cycles [128, 129].
Summarizing, available evidence supports the use of
GnRH agonist trigger as a helpful approach in women
with moderate and/or high risk for OHSS. In fact, in
women with an extreme response to stimulation a GnRH
agonist trigger will be followed by a "freeze-all" strategy to
eliminate OHSS risk, while in patients with a low-
moderate OHSS risk the GnRH-agonist trigger followed
by intensive luteal phase support could allow fresh trans-
fer with good, albeit inferior, reproductive outcome and a
significantly reduced risk of OHSS. Finally, in low OHSS
risk patients, a GnRH agonist trigger with modified luteal
support (hCG rescue bolus after oocyte retrieval) could be
an alternative to conventional hCG trigger, given the ex-
cellent pregnancy rates [130] while GnRH-a and hCG may
be offered concomitantly, 35–37 h prior to oocyte retrieval
(i.e. dual trigger) or 40 h and 34 h prior to oocyte retrieval
respectively, i.e. double trigger, in women with abnormal
final follicular maturation [127].
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duces the possibility of an “exogenous progesterone-
free” luteal phase, that relies solely on endogenous
progesterone production from the corpus luteum driven
by small boluses of LH activity (hCG) administered
during luteal phases [130, 131]. This innovative op-
tion for luteal phase support needs to be corrobo-
rated in future large trials but it could bring an end
to inconvenient vaginal discharge and/or to painful
intramuscular injections of progesterone [108].
Donor and/or frozen-thawed cycles
Due to increased mean age of maternity in developed
countries, IVF using donor oocytes is an increasingly
used infertility treatment option for women with irre-
versible ovarian function loss or primary ovarian failure
[132] showing a pregnancy and implantation rates in oo-
cyte donation cycles higher than in standard IVF/ICSI
cycles [133]. In these cases, the support of the luteal is
an essential prerequisite. In addition, as explained above,
more and more frozen-thawed embryo transfers (FET)
are employed with the aim of avoiding OHSS in high-
risk patients. FET makes it possible for the embryos gen-
erated by IVF and ICSI to be stored and utilized later,
with a segmentation of the IVF cycle, separating the
ovarian stimulation and trigger from the fresh transfer,
and vitrifying all embryos for subsequent transfer in
frozen thawed cycles.
Moreover, not only for reducing the OHSS risk, in re-
cent years the amount of FET cycles has dramatically in-
creased due to the trend towards transferring fewer
embryos after a fresh IVF cycle, and as a result of im-
proved laboratory techniques [134, 135] until to the
emerging “freeze-all” policy as an alternative to fresh
embryo transfer (ET) to improve IVF outcomes [106]. A
recent prospective, observational, cohort study has
suggested that the “freeze-all” policy is advantageous
when compared with fresh ETs [136]. Clinical (RR
1.29, 95 % CI 1.05 to 1.59) and ongoing pregnancy
(RR 1.28, 95 % CI 1.01 to 1.62) rates were signifi-
cantly better after FET [136]. In addition, a recent
meta-analysis of observational studies has shown that
singleton pregnancies after FET are associated with a
lower risk of obstetric outcomes, such as small for
gestational age baby (RR 0.45, 95 % CI 0.30 to 0.66)
and preterm birth (RR 0.84, 95 % CI 0.78 to 0.90)
[137].
Unlike the complex ovarian stimulation protocols of
IVF and ICSI cycles, in the FET cycles, the primary tar-
get is limited to adequate preparation of the endomet-
rium to receive the thawed embryos. The endometrial
preparation can be achieved by means of two different
methods, a natural cycle (NC) which consists of using
endogenous sex steroids production from developingfollicles in patients with regular ovulatory cycles and the
artificial cycles (AC), where the endocrine preparation of
the endometrium is achieved by sequential administra-
tion of estrogens and progestogens to mimic a normal
cycle, more suitable for women without regular ovula-
tory cycles. The entire success of the NC-FET cycle de-
pends on the correct identification of ovulation and
calculation of the likely subsequent period of optimal
endometrial receptivity [138, 139]. The identification of
ovulation is based on detecting the spontaneous LH
surge, therefore LH levels need to be regularly (daily)
monitored in blood or urine samples, because it is as-
sumed that ovulation will occur 36 – 40 h after LH peak
[140]. Unfortunately, the LH surges in urine lag up to
21 h behind the appearance of the blood surge, creating
difficulties in correct assessing of data. To overcome
these problems, a modified-NC (mNC) has been pro-
posed, which consists of hCG triggering when dominant
follicle is of optimal size (>17 mm), after an ultrasound
evaluation to ensure the appropriate timing of hCG
administration.
In the AC-FET the timing of embryo thawing and
transfer is planned according to the moment of proges-
terone supplementation but the sequential administra-
tion of exogenous sex steroids does not guarantee
complete pituitary suppression (at least 5 % of early lu-
teinizations, [141]), putting the endometrium at risk of
early exposure to progesterone. Also for the AC cycle, a
modified AC-FET (mAC) has been proposed consisting
in the co-treatment with GnRH agonist in order to
down-regulate the pituitary and prevent early follicular
luteinizations [142].
A recent meta-analysis regarding the optimal endo-
metrial preparation method in FET revealed no sig-
nificant advantage of one specific approach to prepare
the endometrium for FET in terms of clinical preg-
nancy rates or live birth rates [142]. In particular, no
significant benefit of true NC-FET versus modified
NC-FET with regard to clinical pregnancy (OR 0.91,
95 % CI 0.74 to 1.10), ongoing pregnancy (OR 1.0, 95
% CI 0.66 to 1.60) or live birth (OR 1.0, 95 % CI 0.63
to 1.60) was observed. Also luteal phase support was
evaluated as potential influencing factor on pregnancy
rate but the meta-analysis concludes that currently
there is too little evidence supporting a positive effect
of luteal phase support in patients undergoing NC-
FET [132]. More recently, a retrospective study evalu-
ating 228 patients showed that progesterone for luteal
phase supplementation decreases miscarriage rate and
improves live birth rate in NC-FET cycles [143] but,
due to different study designs, the overall conflicting
results of the available studies, do not make it pos-
sible to conclude a positive effect of luteal phase sup-
port in patients undergoing NC-FET [144].
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timing of progesterone starting and routes of adminis-
tration in donor and/or FET cycles. A Cochrane re-
view [145] analyzed the most effective endometrial
preparation for women undergoing embryo transfer
with frozen embryos and with embryos derived from
donated oocytes. Starting progesterone on the day of
oocyte aspiration (OR 1.92, 95 % CI 1.08 to 3.42) or
on the day after (OR 1.81, 95 % CI 1.01 to 3.24) led
to higher pregnancy rate than when progesterone was
started the day before oocyte retrieval [145]. However,
no difference was found between starting progester-
one the day of oocyte aspiration or the day after (OR
0.94, 95 % CI 0.53 to 1.68) [95, 145]. Finally, no dif-
ferences were found (OR 0.75, 95 % CI 0.24 to 2.34)
between starting one or two days before the oocyte
retrieval when the transfer is performed on blastocyst
stage [145].
As regards progesterone route of administration, no
statistical significant difference was detected in live-
birth and clinical pregnancy rate between vaginal and
intramuscular administration [145]. On the contrary,
in a retrospective cohort study [146] women supple-
mented with vaginal progesterone gel had significantly
lower rate of clinical pregnancy (36.9 % vs. 51.1 %,
respectively) and live birth (24.4 % vs. 39.1 %, re-
spectively) compared with intramuscular progesterone.
The benefit of intramuscular route could be explained
with the higher and continuous serum progesterone
levels that act relaxing uterus and reducing the fre-
quency of endometrial waves in the luteal phase that
are associated with lower pregnancy rates [73]. More-
over, the booster injection of intramuscular progester-
one (50 mg IM, once every 3 days) did not improved
the pregnancy rates of patients who received vaginal
progesterone (100 mg, three times daily) [147].
The worst results in vaginal progesterone group prob-
ably depend on the dosage of vaginal progesterone. In a
retrospective study [148] patients treated with vaginal
progesterone gel twice daily had a lower risk of preg-
nancy loss compared with women treated once a day
(43.7 % vs. 67.4 %, respectively) resulting in a delivery
rate (20.5 % vs. 8.7 %, respectively) more than two-fold
higher [148]. However, considering recipients who re-
ceived vitrified blastocysts on day 6, no statistical differ-
ences were seen in implantation and pregnancy rate
between vaginal and intramuscular progesterone luteal
phase support [149].
Very few data are available regarding the best dos-
age of progesterone administration. A recent study
seems to demonstrate that the optimal dose of intra-
muscular progesterone to for luteal phase support
ranges between 50 and 100 mg/day [150]. In fact, that
dose lets to reach progesterone blood levels similar tothose observed during the mid-luteal phase of a spon-
taneous ovulatory cycle. Moreover, an increase in pro-
gesterone dosage could be useful in donor and/or
frozen-thawed AC cycles when the endometrial pat-
tern at ultrasound is non-homogeneous hyperechoic
in mid-luteal phase [151].
Conclusions
Current data do not completely explain the clinical sig-
nificance of LPD and its treatment. Several mechanisms
of the implantation physiology and of “implantation win-
dow” are still not completely understood and are diffi-
cult to study owing to the lack of adequate tools for
assessing endometrial receptivity. Future perspectives
should concern endometrial competence evaluation,
with the aim of revealing its physiologic mechanisms
and to identify a correct diagnostic test for LPD in order
to recognize it when it occurs in infertile couples.
In fact, LPD, is not univocally considered an infertility
factor, and, even if it can be associated with infertility, it
should be treated only in selected cases. The correct ap-
proach to the treatment of LPD is the identification and
correction of any underlying condition, such as hypothal-
amic amenorrhea, thyroid and prolactin disorders, obesity
and PCOS and during COS for IVF cycles. The available
scientific literature is in agreement that in all gonado-
tropin COS/COH cycles for IVF and non-IVF cycles, pro-
gesterone supplementation is needed for luteal phase
support, showing an improvement of the main reproduct-
ive outcomes. The protocols of luteal phase support with
progesterone change according to the type of protocol of
ovarian stimulation, i.e. conventional or non-conventional
COH. Among different routes of administrations, there
are no statistically significant differences between intra-
muscular progesterone and the others routes (vaginal, oral
and rectal) for IVF cycles, fresh and FET, and the optimal
timing and doses are not yet known.
Much of the current scientific evidence is based on re-
views and meta-analyses of observational studies and on
few RCTs, thus the future perspectives should take into
consideration the implementation of randomized trials
and the evaluation of the promising efficacy of subcuta-
neous progesterone at high-doses in the new COH cy-
cles in which GnRH agonist are used to trigger multiple
ovulation. Thus, at the moment, the scientific debate still
remains open regarding progesterone administration
protocols, in particular routes of administration, dose
and timing and the potential association with other
drugs, and further research is still needed.
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